Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis (IXORA-P)

10 czerwca 2020 zaktualizowane przez: Eli Lilly and Company

A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients With Moderate-to-Severe Plaque Psoriasis

The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.

Przegląd badań

Status

Zakończony

Warunki

Łuszczyca plackowata

Interwencja / Leczenie

Szczegółowy opis

The purpose of this study is to evaluate both the safety and efficacy of ixekizumab dosing regimens. There are 3 study periods: Screening Period, Blinded Treatment Dosing Period, and Post-Treatment Follow-Up.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

1257

Faza

Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

Argentyna
- - Buenos Aires, Argentyna, C1425DKG
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Mendoza, Argentyna, 5500
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Australia
- - Benowa, Australia, 4217
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Carlton, Australia, 3053
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Darlinghurst, Australia, 2010
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Fremantle, Australia, 6160
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Phillip, Australia, 02606
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Woolloongabba, Australia, 4102
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Czechy
- - Brno, Czechy, 656 91
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Novy Jicin, Czechy, 741 01
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Plzen-Bory, Czechy, 305-99
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Praha, Czechy, 100 34
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Japonia
- - Osaka, Japonia, 545-8586
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Takaoka, Japonia, 9330871
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Tsu, Japonia, 514-8507
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Kanada
- - Barrie, Kanada, L4M 6L2
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Calgary, Kanada, T2G 1B1
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Halifax, Kanada, B3H1Z2
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Hamilton, Kanada, L8N1V6
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - London, Kanada, N6A 3H7
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Markham, Kanada, L3P1X2
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Montreal, Kanada, H2K4L5
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Oakville, Kanada, L6J7W5
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Peterborough, Kanada, K9J 5K2
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Quebec, Kanada, G1V 4X7
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Richmond Hill, Kanada, L4B 1A5
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Sherbrooke, Kanada, J1J 2G2
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Surrey, Kanada, V3V 0C6
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Waterloo, Kanada, N2J 1C4
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Windsor, Kanada, N8W 1E6
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Meksyk
- - Mexicali, Meksyk, 21100
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Mexico City, Meksyk, 3100
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Monterrey, Meksyk, 64060
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Morelia, Meksyk, CP 58249
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Niemcy
- - Berlin, Niemcy, 10789
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Darmstadt, Niemcy, 64283
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Kiel, Niemcy, 24148
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Mahlow, Niemcy, 15831
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Munster, Niemcy, 48159
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Polska
- - Bialystok, Polska, 15-351
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Gdansk, Polska, 80-546
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Kielce, Polska, 25-316
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Krakow, Polska, 30-438
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Lodz, Polska, 90-265
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Swidnik, Polska, 21-040
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Szczecin, Polska, 70-332
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Wroclaw, Polska, 51-318
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Portoryko
- - Caguas, Portoryko, 00727
    - Office of Dr. Samuel Sanchez PSC
  - Carolina, Portoryko, 00985
    - Office of Dr. Alma M. Cruz
  - Ponce, Portoryko, 00716
    - Ponce School of Medicine CAIMED Center
  - San Juan, Portoryko, 00909
    - GCM Medical Group PSC
  - San Juan, Portoryko, 00918
    - Mindful Medical Research
Republika Korei
- - Bucheon, Republika Korei, 420-717
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Pusan, Republika Korei, 602-739
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Seongnam, Republika Korei, 463-707
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Seoul, Republika Korei, 100799
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Rumunia
- - Bucuresti, Rumunia, 011025
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Cluj Napoca, Rumunia, 400006
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Constanta, Rumunia, 900125
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Craiova, Rumunia, 200642
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Stany Zjednoczone
- Alabama
  - Birmingham, Alabama, Stany Zjednoczone, 35205
    - Total Skin and Beauty Dermatology Center PC
- California
  - Anaheim, California, Stany Zjednoczone, 92801
    - Anaheim Clinical Trials, LLC
  - Beverly Hills, California, Stany Zjednoczone, 90212
    - David Stoll, M.D.
  - Los Angeles, California, Stany Zjednoczone, 90045
    - Dermatology Research Associates
  - Sacramento, California, Stany Zjednoczone, 95819
    - Center for Dermatology and Laser Surgery
  - San Diego, California, Stany Zjednoczone, 92108
    - Medical Center for Clinical Research
  - San Diego, California, Stany Zjednoczone, 92123
    - University Clinical Trials, Inc.
  - Santa Monica, California, Stany Zjednoczone, 90404
    - Clinical Science Institute
- Colorado
  - Denver, Colorado, Stany Zjednoczone, 80209
    - Cherry Creek Research, Inc
- Florida
  - Coral Gables, Florida, Stany Zjednoczone, 33134
    - Florida Academic Dermatology Centers
  - DeLand, Florida, Stany Zjednoczone, 32720
    - Avail Clinical Research LLC
  - Jacksonville, Florida, Stany Zjednoczone, 32216
    - Jacksonville Center for Clinical Research
  - Ocala, Florida, Stany Zjednoczone, 34471
    - Renstar Medical Research
  - Ormond Beach, Florida, Stany Zjednoczone, 32174
    - Ameriderm Research
  - Tampa, Florida, Stany Zjednoczone, 33624
    - University of South Florida
- Georgia
  - Atlanta, Georgia, Stany Zjednoczone, 30342
    - Advanced Medical Research
- Illinois
  - Darien, Illinois, Stany Zjednoczone, 60561
    - University Dermatology
- Indiana
  - Evansville, Indiana, Stany Zjednoczone, 47714
    - Deaconess Clinic Inc
  - Indianapolis, Indiana, Stany Zjednoczone, 46256
    - Dawes Fretzin Clinical Research
  - South Bend, Indiana, Stany Zjednoczone, 46617
    - The South Bend Clinic
- Kansas
  - Overland Park, Kansas, Stany Zjednoczone, 66215
    - Kansas City Dermatology, PA
  - Wichita, Kansas, Stany Zjednoczone, 67207
    - Heartland Research Associates
- Kentucky
  - Louisville, Kentucky, Stany Zjednoczone, 40202
    - Dermatology Specialist
- Louisiana
  - Lake Charles, Louisiana, Stany Zjednoczone, 70605
    - Dr. Shondra Smith MD
- Maryland
  - Rockville, Maryland, Stany Zjednoczone, 20850
    - DermAssociates, P.C.
- Massachusetts
  - Beverly, Massachusetts, Stany Zjednoczone, 01915
    - ActivMed Practices & Research, Inc
- Missouri
  - Saint Louis, Missouri, Stany Zjednoczone, 63117
    - Central Dermatology PC
- New Hampshire
  - Newington, New Hampshire, Stany Zjednoczone, 03801
    - ActivMed Practices & Research, Inc
- New Jersey
  - East Windsor, New Jersey, Stany Zjednoczone, 08520
    - Psoriasis Treatment Center of Central New Jersey
- New Mexico
  - Albuquerque, New Mexico, Stany Zjednoczone, 87106-5239
    - Academic Dermatology Associates
- New York
  - New York, New York, Stany Zjednoczone, 10029
    - Mount Sinai School of Medicine Dermatology Clinical Trials
  - Rochester, New York, Stany Zjednoczone, 14623
    - Skin Search of Rochester, Inc
- North Carolina
  - Chapel Hill, North Carolina, Stany Zjednoczone, 27516
    - University of North Carolina Dermatology and Skin Cancer Center
  - Wilmington, North Carolina, Stany Zjednoczone, 28401
    - PMG Research of Wilmington, LLC
  - Wilmington, North Carolina, Stany Zjednoczone, 28405
    - Wilmington Dermatology Center
  - Winston-Salem, North Carolina, Stany Zjednoczone, 27103
    - Piedmont Medical Research
- Ohio
  - Cleveland, Ohio, Stany Zjednoczone, 44106-5055
    - University Hospitals of Cleveland
- Oklahoma
  - Tulsa, Oklahoma, Stany Zjednoczone, 74135
    - Healthcare Research Consultant
- Oregon
  - Portland, Oregon, Stany Zjednoczone, 97210
    - Oregon Dermatology and Research Center
  - Portland, Oregon, Stany Zjednoczone, 97223
    - Oregon Medical Research Center
- Pennsylvania
  - Exton, Pennsylvania, Stany Zjednoczone, 19341
    - Dermatology and Skin Surgery Center
  - Pittsburgh, Pennsylvania, Stany Zjednoczone, 15213
    - University of Pittsburgh Medical Center
  - Wyomissing, Pennsylvania, Stany Zjednoczone, 19610
    - Pennsylvania Regional Center for Arthritis & Osteoarthritis
  - Yardley, Pennsylvania, Stany Zjednoczone, 19067
    - Yardley Dermatology
- Rhode Island
  - Johnston, Rhode Island, Stany Zjednoczone, 02919
    - Clinical Partners LLC
- South Carolina
  - Mount Pleasant, South Carolina, Stany Zjednoczone, 29464
    - Coastal Carolina Research Center, Inc.
- Tennessee
  - Knoxville, Tennessee, Stany Zjednoczone, 37922
    - The Skin Wellness Center PC
- Texas
  - Austin, Texas, Stany Zjednoczone, 78705
    - Austin Dermatology Associates
  - Dallas, Texas, Stany Zjednoczone, 75246
    - Menter Dermatology Research Institute
  - Houston, Texas, Stany Zjednoczone, 77004
    - Center For Clinical Studies
  - Houston, Texas, Stany Zjednoczone, 77065
    - Center For Clinical Studies
  - Pflugerville, Texas, Stany Zjednoczone, 78660
    - Pflugerville Dermatology Clinical Research Center
  - San Antonio, Texas, Stany Zjednoczone, 78229
    - Clinical Trials of Texas, Inc.
  - Webster, Texas, Stany Zjednoczone, 77598
    - Center For Clinical Studies
- Utah
  - Salt Lake City, Utah, Stany Zjednoczone, 84132
    - University of Utah Medical Center
- Virginia
  - Norfolk, Virginia, Stany Zjednoczone, 23507
    - Virginia Clinical Research
- Washington
  - Seattle, Washington, Stany Zjednoczone, 98101
    - Dermatology Associates
  - Tacoma, Washington, Stany Zjednoczone, 98405
    - MultiCare Health System
  - Wenatchee, Washington, Stany Zjednoczone, 98801
    - Wenatchee Valley Hospital & Clinics
Tajwan
- - Tainan, Tajwan, 70166
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Taipei, Tajwan, 10048
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Węgry
- - Budapest, Węgry, 1238
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Debrecen, Węgry, 4032
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Oroshaza, Węgry, 5901
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  - Szolnok, Węgry, 5000
    - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

Present with chronic plaque psoriasis for at least 6 months prior to enrollment
At least 10% BSA of psoriasis at screening and at enrollment
sPGA score of at least 3 and PASI score of at least 12 at screening and at enrollment
Candidates for phototherapy and/or systemic therapy
Participant must agree to use reliable method of birth control during the study; women must continue using birth control for at least 12 weeks after stopping treatment

Exclusion Criteria:

Predominant pattern of pustular, erythrodermic, or guttate forms of psoriasis
History of drug-induced psoriasis
Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to enrollment and during the study
Received systemic non-biologic psoriasis therapy or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to enrollment
Concurrent or recent use of any biologic agent
Have participated in any study with ixekizumab
Received a live vaccination within 12 weeks prior to enrollment
Serious disorder or illness other than psoriasis
Ongoing or serious infection within the last 12 weeks or evidence of tuberculosis
Major surgery within 8 weeks of baseline, or will require surgery during the study
Breastfeeding or nursing (lactating) women

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

Główny cel: Leczenie
Przydział: Randomizowane
Model interwencyjny: Przydział równoległy
Maskowanie: Podwójnie

Liczba ramion

Broń i interwencje

Grupa uczestników / Arm	Interwencja / Leczenie
Eksperymentalny: 80 mg Ixekizumab Q2W 160 milligrams (mg) ixekizumab given as 2 subcutaneous (SQ) injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 2 weeks (Q2W) to week 52. Placebo administered SQ, Q2W to maintain blind.	Lek: Placebo Administrowany SQ Lek: Ixekizumab Administered SQ Inne nazwy: LY2439821
Eksperymentalny: 80 mg Ixekizumab Q4W 160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 4 weeks (Q4W) to week 52. Placebo administered SQ, Q2W to maintain blind.	Lek: Placebo Administrowany SQ Lek: Ixekizumab Administered SQ Inne nazwy: LY2439821
Eksperymentalny: 80 mg Ixekizumab Q4W/Q2W 160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.	Lek: Placebo Administrowany SQ Lek: Ixekizumab Administered SQ Inne nazwy: LY2439821
Eksperymentalny: 80 mg Ixekizumab Q2W Maximum Extended Enrollment (ME2) Cohort 160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q2W to week 52. Placebo administered SQ, Q2W to maintain blind.	Lek: Placebo Administrowany SQ Lek: Ixekizumab Administered SQ Inne nazwy: LY2439821
Eksperymentalny: 80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort 160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q4W to week 52. Placebo administered SQ, Q2W to maintain blind.	Lek: Placebo Administrowany SQ Lek: Ixekizumab Administered SQ Inne nazwy: LY2439821
Eksperymentalny: 80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort 160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.	Lek: Placebo Administrowany SQ Lek: Ixekizumab Administered SQ Inne nazwy: LY2439821

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku	Opis środka	Ramy czasowe
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of (0,1) Ramy czasowe: Week 52	The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 52 were considered non-responders for Non-Responder Imputation (NRI) analysis.	Week 52
Percentage of Participants Achieving 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Ramy czasowe: Week 52	The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants who did not meet the clinical response criteria or had missing data at Week52 were considered non-responders for NRI analysis.	Week 52

Miary wyników drugorzędnych

Miara wyniku	Opis środka	Ramy czasowe
Percentage of Participants Achieving sPGA (0) Ramy czasowe: Week 52	The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 52 were considered non-responders for Non-Responder Imputation (NRI) analysis.	Week 52
Percentage of Participants Achieving PASI 90 Ramy czasowe: Week 52	PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).	Week 52
Percentage of Participants Achieving PASI 100 Ramy czasowe: Week 52	The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).	Week 52
Change From Baseline in PASI Ramy czasowe: Baseline, Week 52	The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. Least Squares mean (LSmean) was calculated using Mixed-Effects Model of Repeated Measures (MMRM) analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.	Baseline, Week 52
Percent Improvement in PASI Ramy czasowe: Baseline, Week 52	The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. Least Squares mean (LSmean) was calculated using Mixed-Effects Model of Repeated Measures (MMRM) analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.	Baseline, Week 52
Mean Change From Baseline in Percent Body Surface Area (BSA) Involvement Ramy czasowe: Baseline, Week 52	The percentage involvement of psoriasis on each participant's body surface area (BSA) was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb. LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.	Baseline, Week 52
Mean Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score Ramy czasowe: Baseline, Week 52	The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail (fn) Ps. This scale is used to evaluate the severity of fn bed Ps and fn matrix Ps by area of involvement in the fn unit. The fn is divided with imaginary horizontal and longitudinal lines into quadrants. Each fn is given a score for fn bed Ps (0 to 4) and fn matrix Ps (0 to 4) depending on presence (score of 1) or absence (score of 0) of any of the features of fn bed and fn matrix Ps in each quadrant. The NAPSI score of a fn is sum of scores in fn bed and fn matrix from each quadrant (maximum of 8). Each fn is evaluated, then the sum of all fn equals the total NAPSI score with a range from 0 to 80 (0 indicates no Ps, 80 indicates worst Ps). LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.	Baseline, Week 52
Mean Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score Ramy czasowe: Baseline, Week 52	The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (<10%) to 6 (90-100%) with a total score ranging from 0 (less severity) to 72 (more severity). LS mean change was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.	Baseline, Week 52
Mean Change From Baseline in Palmoplantar PASI (PPASI) Ramy czasowe: Baseline, Week 52	The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no PPASI) to 72 (most severe PPASI). The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.	Baseline, Week 52
Percentage of Participants Achieving an Itch Numeric Rating Scale (Itch NRS) ≥4 Point Reduction From Baseline Ramy czasowe: Baseline, Week 52	The Itch NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours. Participants who did not meet the clinical response criteria or had missing data at Week 52 were considered non-responders for Non-Responder Imputation (NRI) analysis.	Baseline, Week 52
Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Total Score of 0 and 1 (DLQI [0,1]) Ramy czasowe: Week 52	The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment). Participants who did not meet the clinical response criteria or had missing data at Week 52 were considered non-responders for Non-Responder Imputation (NRI) analysis.	Week 52
Change From Baseline in DLQI Total Score Ramy czasowe: Baseline, Week 52	The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment). LS mean change was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.	Baseline, Week 52
Change From Baseline in Itch NRS Score Ramy czasowe: Baseline, Week 52	The Itch NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours. LS mean change from baseline in PSSI was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.	Baseline, Week 52
Change From Baseline in Skin Pain Visual Analog Scale (VAS) Ramy czasowe: Baseline, Week 52	The pain VAS is a participant-administered single-item scale designed to measure Skin pain from Psoriasis using a 0-100 millimeter (mm) horizontal VAS. Overall severity of participant's skin pain from Psoriasis is indicated by placing a single mark on the horizontal 100 mm scale from 0 mm (no skin pain) to 100 mm (severe skin pain). LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.	Baseline, Week 52
Change From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) VAS Ramy czasowe: Baseline, Week 52	EQ-5D-5L is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of 2 components: a descriptive system of the respondent's health and a rating of his/her current health state using a 0 (no pain) to 100mm VAS (severe pain). LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.	Baseline, Week 52
Pharmacokinetics (PK): Trough Concentration at Steady State (Ctrough,ss) of Ixekizumab Ramy czasowe: Predose, Week 4, 12, 24, 36 and 52 Post dose	Trough concentrations at steady state of Ixekizumab were evaluated.	Predose, Week 4, 12, 24, 36 and 52 Post dose
Number of Participants With Anti-Ixekizumab Antibodies Ramy czasowe: Baseline through Week 52	Number of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group.	Baseline through Week 52

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Eli Lilly and Company

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów

1 sierpnia 2015

Zakończenie podstawowe (Rzeczywisty)

1 listopada 2016

Ukończenie studiów (Rzeczywisty)

3 sierpnia 2017

Daty rejestracji na studia

Pierwszy przesłany

30 lipca 2015

Pierwszy przesłany, który spełnia kryteria kontroli jakości

30 lipca 2015

Pierwszy wysłany (Oszacować)

31 lipca 2015

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

17 czerwca 2020

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

10 czerwca 2020

Ostatnia weryfikacja

1 czerwca 2020

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

15988
I1F-MC-RHBP (Inny identyfikator: Eli Lilly and Company)
2015-000190-12 (Numer EudraCT)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Ramy czasowe udostępniania IPD

Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Kryteria dostępu do udostępniania IPD

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Typ informacji pomocniczych dotyczących udostępniania IPD

PROTOKÓŁ BADANIA
SOK ROŚLINNY
CSR

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Placebo

Galderma R&D

Zakończony

Wpływ żelu CD07805/47 na trądzik różowaty

Trądzik różowaty

Niemcy
SamA Pharmaceutical Co., Ltd

Nieznany

Badania kliniczne oceniające skuteczność i bezpieczeństwo HLIM

Ostre zapalenie oskrzeli | Ostra infekcja górnych dróg oddechowych

Republika Korei
National Institute on Drug Abuse (NIDA)

Zakończony

Wpływ dróg podawania konopi indyjskich na wydajność i farmakokinetykę człowieka

Używanie konopi indyjskich

Stany Zjednoczone
AstraZeneca
Parexel; Spandauer Damm 130; 14050; Berlin, Germany

Zakończony

Ocena bezpieczeństwa, tolerancji i farmakodynamiki po podaniu jednej dawki AZD8601 pacjentom płci męskiej z cukrzycą typu II (T2DM)

Mężczyźni z cukrzycą typu II (T2DM)

Niemcy
Akeso

Jeszcze nie rekrutacja

Badanie kliniczne AK120 u młodzieży z umiarkowanym do ciężkiego atopowym zapaleniem skóry

Atopowe zapalenie skóry

Chiny
Heptares Therapeutics Limited

Zakończony

Farmakokinetyka kapsułki doustnej u zdrowych osób z Japonii i rasy kaukaskiej (HTL0018318)

Farmakokinetyka | Problemy z bezpieczeństwem

Zjednoczone Królestwo
Cellmedis
Medical Network Sp. z o.o.

Jeszcze nie rekrutacja

New Topical tReatment Options for Symptomatic patiEnts With Nonerosive gastroesophageaL Reflux dIsease: rEsults oF a Single-center, Randomized, Double-blind, Placebo-controlled Crossover Trial. (The RELIEF Trial) (RELIEF)

GERD (choroba refluksowa przełyku) | NERD

Polska
Soroka University Medical Center

Zakończony

Effect of Probiotics in Childhood Abdominal Pain

Ból brzucha

Izrael
Regado Biosciences, Inc.

Zakończony

Safety, Tolerability and PK/PD of RB006 in a Healthy Volunteer SAD (SC101)

Zdrowy ochotnik

Stany Zjednoczone
West Penn Allegheny Health System

Zakończony

Badanie wzrostu Sunovion u dzieci z łagodną astmą i alergicznym nieżytem nosa

Astma | Alergiczny nieżyt nosa

Stany Zjednoczone

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis (IXORA-P)

A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients With Moderate-to-Severe Plaque Psoriasis

Przegląd badań

Status

Warunki

Interwencja / Leczenie

Szczegółowy opis

Typ studiów

Zapisy (Rzeczywisty)

Faza

Kontakty i lokalizacje

Lokalizacje studiów

Kryteria uczestnictwa

Kryteria kwalifikacji

Wiek uprawniający do nauki

Akceptuje zdrowych ochotników

Płeć kwalifikująca się do nauki

Opis

Plan studiów

Jak projektuje się badanie?

Szczegóły projektu

Liczba ramion

Broń i interwencje

Grupa uczestników / Arm

Interwencja / Leczenie

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku

Opis środka

Ramy czasowe

Miary wyników drugorzędnych

Miara wyniku

Opis środka

Ramy czasowe

Współpracownicy i badacze

Sponsor

Daty zapisu na studia

Główne daty studiów

Rozpoczęcie studiów

Zakończenie podstawowe (Rzeczywisty)

Ukończenie studiów (Rzeczywisty)

Daty rejestracji na studia

Pierwszy przesłany

Pierwszy przesłany, który spełnia kryteria kontroli jakości

Pierwszy wysłany (Oszacować)

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

Ostatnia weryfikacja

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

Opis planu IPD

Ramy czasowe udostępniania IPD

Kryteria dostępu do udostępniania IPD

Typ informacji pomocniczych dotyczących udostępniania IPD

Badania kliniczne na Placebo

Wyszukaj podobne próby

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

CROs by country

CROs in Netherlands

Warunki

Rzadkie choroby

Interwencje lekowe

Suplementy diety

Sponsor / Współpracownicy

Lokalizacje